Antonio Calles, Medical Specialist in Medical Oncology at Gregorio Marañón General University Hospital, shared a post on X:
“Massive news for patients with SCLC.
Lurbinectedin and Atezolizumab maintenance after 1st line chemotherapy and Atezolizumab hits PFS and OS gain.”